Home > Boards > US Listed > Biotechs > Inovio Pharmaceuticals, Inc. (INO)

Is Inovio Stock A Buy After Brazil OKs

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Lakers_w Member Profile
Followed By 13
Posts 3,042
Boards Moderated 1
Alias Born 04/26/07
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/21/2022 4:03:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/18/2022 4:06:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2022 4:04:45 PM
Is 15% Potential Upside Good Enough to Risk Buying Inovio Stock? Analyst Weighs In TipRanks - 12/30/2021 3:49:03 PM
Inovio assumed with Hold at Jefferies with $6 target Seeking Alpha - 12/29/2021 9:55:07 AM
Inovio: Making Progress in the Cervical HSIL Program TipRanks - 12/15/2021 7:12:43 PM
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18 PR Newswire (US) - 12/14/2021 8:00:00 AM
INOVIO starting development of Omicron-specific COVID vaccine candidate Seeking Alpha - 11/30/2021 9:03:04 AM
INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants PR Newswire (US) - 11/30/2021 8:00:00 AM
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201 PR Newswire (US) - 11/16/2021 8:00:00 AM
INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference PR Newswire (US) - 11/15/2021 8:00:00 AM
Inovio Stock at $35 a Share? This Analyst Thinks It’s Possible TipRanks - 11/12/2021 6:22:17 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/9/2021 4:51:53 PM
Inovio targets H1 2022 to share interim data from late-stage trial for COVID-19 shot Seeking Alpha - 11/9/2021 4:37:51 PM
Inovio Pharmaceuticals EPS beats by $0.04, misses on revenue Seeking Alpha - 11/9/2021 4:11:04 PM
INOVIO Reports Third Quarter 2021 Financial Results PR Newswire (US) - 11/9/2021 4:05:00 PM
INOVIO wins FDA clearance to proceed with late-stage study for COVID-19 shot Seeking Alpha - 11/9/2021 8:35:04 AM
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. PR Newswire (US) - 11/9/2021 8:00:00 AM
Inovio Pharmaceuticals Q3 2021 Earnings Preview Seeking Alpha - 11/8/2021 11:47:11 AM
INOVIO Expands Executive Leadership to Prepare for Commercial Operations PR Newswire (US) - 11/5/2021 8:00:00 AM
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India PR Newswire (US) - 11/3/2021 8:00:00 AM
AstraZeneca unit terminates cancer vaccine program with Inovio Seeking Alpha - 10/29/2021 5:54:50 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2021 5:02:40 PM
Inovio COVID-19 vaccine candidate to undergo WHO-sponsored trial Seeking Alpha - 10/28/2021 9:09:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2021 6:11:14 AM
Lakers_w   Friday, 09/10/21 03:51:49 PM
Re: None
Post # of 39842 
Is Inovio Stock A Buy After Brazil OKs Phase 3 Test For Covid Vaccine?
Brazil's national health agency gave Inovio the go-ahead to run a Phase 2 and Phase 3 study of its shot-plus-device Covid vaccine. The company is also planning to conduct the final-phase test in multiple countries with its partner, Advaccine Biopharmaceuticals Suzhou.

Also last month, INO stock popped after the company dosed the first participant in a study to vaccinate against Middle East Respiratory Syndrome, or MERS. The illness is caused by a coronavirus. It's more fatal than Covid, though far less common.

It has big biopharma partners like AZN, REGN.

The revenue picture could change quickly if Inovio succeeds in making an effective coronavirus vaccine. The biotech also has a drug in Phase 3 testing to treat a precancerous condition of the cervix. It's partnered with privately held ApolloBio on that drug.

As of June, 232 funds owned 25% of Inovio stock.

Analysts say it's possible Inovio could still launch its vaccine and device internationally. And, now, Advaccine is partnering on the Phase 3 test. That news, on June 9, sent INO stock flying higher.

Last month, Inovio and Advaccine received regulatory clearance to test a boosting strategy using the experimental Covid vaccine and one from Sinovac Biotechnology. The study will take place in China and test sequential immunizations using the two vaccines.

The firm is also working on a vaccine to target Covid variants. In May, the company said preclinical tests showed the vaccine induced immune responses against the variants first found in the U.K., South Africa and Brazil, as well as the original strain.

In Feb, INO stock soared after a Reddit user called for a short squeeze of the stock. Also helping the biotech company: BlackRock, an investment management firm, upped its stake to more than 14.2 M shares. It now owns 8.4%.

What is important, for now, is watching INO stock as the biotech company works to get back on track in developing coronavirus vaccine. Its DNA approach differs from traditional vaccines and from the newer messenger RNA approach.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences